Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
NCT03664804
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
95
Enrollment
INDUSTRY
Sponsor class
Conditions
Huntington's Disease
Interventions
OTHER:
No Study Drug was Administered in this Study
Sponsor
Hoffmann-La Roche